ArticleNucleic acids research2026
M6AREG 2.0: the landscape of m6A-centered crosstalk with diverse epigenetic regulation.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
m6A-centered crosstalk with epigenetic regulation (m6A-CT) is essential for understanding disease development and drug response. Based on different layers of epigenetic regulation, m6A-CT can be classified into four categories: m6A-centered crosstalk with histone modification (m6A-HistMod), m6A-centered crosstalk with DNA methylation (m6A-DNAMeth), m6A-centered crosstalk with RNA modification (m6A-RNAMod), and m6A-centered crosstalk with non-coding RNA (m6A-ncRNA). However, none of the existing databases has comprehensively provided the crucial data regarding m6A-CT. Therefore, a significant update was made to the M6AREG database. This updated version includes 713 entries for m6A-HistMod, 300 entries for m6A-DNAMeth, 483 entries for m6A-RNAMod, and 939 entries for m6A-ncRNA. These types of crosstalk can alter cellular pathways and processes, ultimately leading to the development of 271 categories of diseases and the response data of 205 drugs, which are regulated by 585 epigenetic regulators (including 138 regulatory proteins and 447 non-coding RNAs). Given that these data are critical for identifying diagnostic biomarkers and therapeutic targets, discovering drugs that target m6A modification, and developing combinatorial therapies to overcome drug resistance or immune evasion, this update will greatly enhance the impact of M6AREG and hold significant importance for m6A-relevant studies. The database is currently accessible to all users at: https://idrblab.org/m6areg/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.